Department of Medicine 5 – Haematology and Oncology

Allogeneic Hematopoietic Cell Transplantation in Patients <= 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial- (2021) Bornhaeuser M, Schliemann C, Schetelig J, Rollig C, Kramer M, Glass B, Platzbecker U, et al. Conference contribution Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning (2021) Eckardt JN, Rollig C, Kramer M, Stasik S, Georgi JA, Heisig P, Kroschinsky FP, et al. Conference contribution Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial (2021) Zimmermann H, Koenecke C, Dreyling MH, Pott C, Duhrsen U, Hahn D, Meidenbauer N, et al. Conference contribution The CAR- Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL (2021) Rejeski K, Perez-Perez A, Iacoboni G, Penack O, Buecklein VL, Jentzsch L, Mougiakakos D, et al. Conference contribution A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts (2021) Mackensen A, Hanssens L, Stelljes M, Bethge WA, Feuchtinger T, Kuenkele A, Aigner M, et al. Conference contribution IL-33-induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation (2021) Faas M, Ipseiz N, Ackermann J, Culemann S, Grüneboom A, Schröder F, Rothe T, et al. Journal article Increased Levels of sCD30 Have No Impact on the Incidence of Early ABMR and Long-Term Outcome in Intermediate-Risk Renal Transplant Patients With Preformed DSA (2021) Drasch T, Bach C, Luber M, Spriewald B, Utpatel K, Büttner-Herold M, Banas B, Zecher D Journal article Neoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperitoneal sarcomas: feasibility, efficacy, toxicity, and long-term outcome (2021) Willner A, Fechner K, Agaimy A, Haller F, Eckstein M, Ott O, Putz F, et al. Journal article More on CD19-CAR T Cells in Systemic Lupus Erythematosus (2021) Mougiakakos D, Krönke G, Schett G Journal article, Letter BNT211: A PHASE I/II TRIAL TO EVALUATE SAFETY AND EFFICACY OF CLDN6 CAR-T CELLS AND VACCINE-MEDIATED IN VIVO EXPANSION IN PATIENTS WITH CLDN6-POSITIVE ADVANCED SOLID TUMORS (2021) Mackensen A, Koenecke C, Haanen J, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, et al. Conference contribution